Skip to main content
Ascelia Pharma logo

Ascelia Pharma — Investor Relations & Filings

Ticker · ACE ISIN · SE0010573113 LEI · 5493002YR9VCJJPWYN08 ST Manufacturing
Open in API
Filings indexed 295 across all filing types
Latest filing 2024-08-09 Capital/Financing Update
Country SE Sweden
Listing ST ACE

About Ascelia Pharma

https://www.ascelia.com/

Ascelia Pharma is a biotechnology company focused on developing and commercializing novel drugs for orphan oncology. The company aims to address unmet medical needs for patients with rare cancer conditions. Its lead product candidate, Orviglance, is an oral manganese-based contrast agent for magnetic resonance imaging (MRI). It is designed to improve the detection and visualization of liver metastases, particularly in adult patients with severely impaired kidney function for whom existing contrast agents may be contraindicated. The company's strategy involves identifying, developing, and commercializing innovative treatments for niche cancer-related conditions.

Recent filings

Filing Released Lang Actions
Ascelia Pharma offentliggör slutliga villkor i företrädesemission
Capital/Financing Update Classification · 98% confidence The document is a press release published on August 9, 2024, detailing the final terms of a rights issue ("Företrädesemission") involving the issuance of units (shares and warrants). It discusses subscription prices, timelines for trading rights (uniträtter) and subscription periods, capital raised (MSEK), and dilution effects. Crucially, it repeatedly mentions that the full details will be provided in a Prospectus expected to be published around August 16, 2024, and explicitly states that this press release is marketing material and not the prospectus itself. Since the document announces the final terms and the upcoming publication of the official offering document (Prospectus), it falls under the category of an announcement related to financing activities and capital structure changes, specifically a rights issue. This aligns best with the 'Capital/Financing Update' (CAP) category, as it is a detailed announcement about the terms of a capital raise, rather than just a general 'Report Publication Announcement' (RPA) which usually just states a report is attached.
2024-08-09 Swedish
Major Shareholding Notification 2024
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding, specifically a 'Sell' transaction by Avanza Bank Holding AB for its pension subsidiary, resulting in a new percentage of voting rights (4.51013%). The structure, including 'Before the transaction', 'After the transaction', and 'Resulting distribution of total holdings', is characteristic of a major shareholding notification. This directly matches the definition for Major Shareholding Notification (MRQ). The document is short and appears to be the official filing itself, not an announcement of a filing.
2024-07-25 English
Major Shareholding Notification 2024
Major Shareholding Notification Classification · 99% confidence The document explicitly details a 'Reason for major shareholding notification' concerning the sale of shares by a holder (Avanza Bank Holding AB for Försäkringsaktiebolaget Avanza Pension). It provides specific figures for 'Shares', 'Directly held voting rights', 'Indirectly held voting rights', and the resulting 'Percentage' after the transaction, culminating in a 'Group total holdings' summary. This structure perfectly matches the definition of a Major Shareholding Notification, which corresponds to the filing code MRQ.
2024-07-22 English
Notice of Extraordinary General Meeting in Ascelia Pharma AB
AGM Information Classification · 100% confidence The document is explicitly titled "Notice of Extraordinary General Meeting in Ascelia Pharma AB". It details the date, time, location, shareholder registration requirements, proxy rules, and the proposed agenda for this meeting. The agenda items include resolutions on amending the Articles of Association and approving a rights issue of units. A meeting notice that details the agenda and proposed resolutions for shareholder voting is the definition of materials shared during a General Meeting. Therefore, the appropriate classification is AGM-R (AGM Information).
2024-07-10 English
Kallelse till extra bolagsstämma i Ascelia Pharma AB
AGM Information Classification · 99% confidence The document is titled "Kallelse till extra bolagsstämma i Ascelia Pharma AB" (Notice of Extraordinary General Meeting in Ascelia Pharma AB). It details the date, time, location, registration requirements, and crucially, the proposed agenda items for the meeting. The agenda includes proposals for changes to the articles of association (Punkt 6), approval of a rights issue of units (Punkt 7), and authorization for the board to issue shares/options to guarantors (Punkt 8). These elements—a formal notice, agenda, and specific proposals for shareholder votes—are characteristic of a document calling for a general meeting. This aligns perfectly with the definition of materials shared for an Annual General Meeting (AGM-R), even though it is an *Extraordinary* General Meeting, as AGM-R covers general meeting materials.
2024-07-10 Swedish
Ascelia Pharma Carries Out a Rights Issue of Units of Approximately SEK 105 Million to Fully Finance the NDA Submission for Orviglance®
Capital/Financing Update Classification · 98% confidence The document is a press release announcing a 'Rights Issue of Units' amounting to approximately SEK 105 Million. It details the purpose (financing NDA submission for Orviglance®), the structure (shares and warrants), subscription periods, and shareholder voting requirements for an upcoming Extraordinary General Meeting (EGM). A rights issue is a specific type of corporate financing activity aimed at raising capital by offering new shares/units to existing shareholders. This directly aligns with the definition of 'Capital/Financing Update' (CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a general regulatory filing (RNS), as it describes a specific, planned capital action.
2024-07-10 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.